Skip to main content
Calcium and Magnesium icons from periodic table.

When it comes to ureteral stents, urine calcium (Ca) and magnesium (Mg) salt deposits can contribute to stent complications such as encrustation.1,2 The cause and rate of encrustation is multifactorial and can include factors such as body chemistry and medical condition of the patient, stent indwell time, and surface material properties of the stent.2-4 The Tria stent is the only commercially available stent that may help control the accumulation of Ca and Mg salts.5,6


Tria Ureteral Stent Playback.



PercuShield™ Technology

Designed to provide protection against salt accumulation.5,6 This technology is also embedded on the inner and outer surfaces of the stent to provide protection throughout the entire in dwell.

glass mirror icon.


stopwatch icon.

Longer Indwell Times

Tria features biocompatible material designed to enable indwell time up to 365 days,5,7 which is especially important in times with limited OR access due to the COVID-19 pandemic.


Stiffer During Placement

The Tria Stent is designed to be stiffer during placement to navigate patient anatomy while softening by over 40% at body temperature,5,8 which may promote greater patient tolerability.9

location icon.


vertical ruler icon.

Varying Sizes

Available in soft and firm stent durometers and in an expansive range of diameters and lengths to cover a variety of patient types.


Your Partner In Innovation

Together with our urology partners, Boston Scientific is committed to innovations in stone management. Fueled by physician feedback across the US and Europe, we identified the following two unmet needs when it comes to stents: maximizing patient comfort and minimizing stent encrustation.10 That’s why Boston Scientific embarked on a six-year journey, investing $9 million to develop a ureteral stent that addresses physicians’ needs and helps them optimize patient care.